Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone

CUMBERLAND PHARMACEUTICALS INC

Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.
SciClone granted exclusive rights to register, promote, and distribute Vibativ in China.
Companies plan to launch Vibativ in China later in 2025.
Vibativ is a once-daily IV antibiotic designed to treat multidrug-resistant Gram-positive bacteria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.